12/19
06:51 am
dmac
Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$26m [Yahoo! Finance]
Low
Report
Individual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$26m [Yahoo! Finance]
12/3
08:28 am
dmac
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia [Yahoo! Finance]
Low
Report
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia [Yahoo! Finance]
12/3
08:25 am
dmac
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
Medium
Report
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
11/16
08:06 am
dmac
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate [Yahoo! Finance]
11/15
08:04 am
dmac
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
11/13
04:47 pm
dmac
DiaMedica Therapeutics GAAP EPS of -$0.15 in-line [Seeking Alpha]
Low
Report
DiaMedica Therapeutics GAAP EPS of -$0.15 in-line [Seeking Alpha]
11/13
04:26 pm
dmac
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results [Yahoo! Finance]
11/13
04:20 pm
dmac
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
Low
Report
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
11/13
04:05 pm
dmac
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Medium
Report
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
11/12
08:28 am
dmac
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference [Yahoo! Finance]
Low
Report
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference [Yahoo! Finance]
11/12
08:23 am
dmac
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
Low
Report
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
11/6
08:53 am
dmac
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 [Yahoo! Finance]
Low
Report
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 [Yahoo! Finance]
11/6
08:32 am
dmac
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
Low
Report
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
10/9
08:31 am
dmac
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia [Yahoo! Finance]
Medium
Report
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia [Yahoo! Finance]
10/9
08:27 am
dmac
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Low
Report
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
10/8
06:56 am
dmac
DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$9.05m [Yahoo! Finance]
Medium
Report
DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$9.05m [Yahoo! Finance]
10/7
08:10 am
dmac
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $7.00 price target on the stock.
Medium
Report
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $7.00 price target on the stock.